QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
plans to develop a proprietary new version of a QuantiFERON®-based
tuberculosis (TB) test dedicated and tailored to the needs of
low-resource regions with a high disease burden of TB.
The new testing solution, QuantiFERON®-TB Access (QFT®
Access), is designed to pair ultrasensitive digital detection of latent
TB infection with a complete workflow created with a focus on cost
efficiency and ease of use. QIAGEN is developing QFT Access in a new
partnership with Ellume, an Australian developer of high-performance
digitally-enabled diagnostics. Clinical trials for QFT Access are
planned to start in 2019, and commercialization is expected to begin in
QFT Access has been designed to advance TB control in areas with limited
infrastructure, including countries in Asia, Africa and Latin America.
The World Health Organization (WHO) has classified a group of 30
countries in these regions as high-burden, representing an estimated 85%
of the global TB burden. QIAGEN intends to work with the WHO, various
non-governmental organizations and governments to support their TB
control efforts, in particular to achieve the goals set for the WHO's
End TB Strategy.
“QuantiFERON-TB Gold Plus is rapidly winning adoption in developed
markets as an important way to detect latent TB infections and prevent
patients from developing the active form of this potentially deadly
disease,” said Thierry Bernard, Senior Vice President of QIAGEN’s
Molecular Diagnostics Business Area. “Despite the urgent need for more
latent TB testing in low-resource, high-burden parts of the world, a
lack of infrastructure and shortage of trained technicians make adoption
of modern tests challenging. QuantiFERON-TB Access offers a novel
solution for this challenge by combining the proven clinical insights of
QuantiFERON-TB with Ellume’s digital technologies to deliver
cost-efficient results quickly and without need for a laboratory, and a
further signal of our support in the global fight against TB.”
Please find the full press release here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190106005115/en/